J. Campestrini

发表

Pharmacokinetics of enteric‐coated mycophenolate sodium in stable pediatric renal transplant recipients

R. Schmouder, Wei Zhu, W. Niederberger, 2005, Pediatric transplantation.

Vildagliptin, a Novel Dipeptidyl Peptidase IV Inhibitor, Has No Pharmacokinetic Interactions With the Antihypertensive Agents Amlodipine, Valsartan, and Ramipril in Healthy Subjects

Yan-Ling He, G. Sunkara, M. Ligueros-Saylan, 2008, Journal of clinical pharmacology.

The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin

Yan-Ling He, K. Lasseter, W. Dole, 2007, European Journal of Clinical Pharmacology.

Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers

S. Leon, Yan-Ling He, B. Flannery, 2008, Current medical research and opinion.

The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers.

Yan-Ling He, W. Dole, R. Sabo, 2008, British journal of clinical pharmacology.

Pharmacokinetics and Pharmacodynamics of Vildagliptin in Patients with Type 2 Diabetes Mellitus

J. Holst, Yan-Ling He, C. Deacon, 2007, Clinical pharmacokinetics.

Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects*

Yan-Ling He, G. Sunkara, Yibin Wang, 2007, Current medical research and opinion.

Dose Proportionality and the Effect of Food on Vildagliptin, a Novel Dipeptidyl Peptidase IV Inhibitor, in Healthy Volunteers

Yan-Ling He, G. Sunkara, W. Dole, 2007, Journal of clinical pharmacology.

The Absolute Oral Bioavailability and Population-Based Pharmacokinetic Modelling of a Novel Dipeptidylpeptidase-IV Inhibitor, Vildagliptin, in Healthy Volunteers

Yan-Ling He, B. Sadler, R. Sabo, 2007, Clinical pharmacokinetics.

Pharmacokinetics Of Indacaterol After Single And Multiple Inhaled Doses

S. Khindri, R. Woessner, F. Picard, 2010, ATS 2010.

Automated and sensitive method for the determination of formoterol in human plasma by high-performance liquid chromatography and electrochemical detection.

J. Godbillon, J. Lecaillon, J. Campestrini, 1997, Journal of chromatography. B, Biomedical sciences and applications.

Effect of food on the bioavailability of triclabendazole in patients with fascioliasis.

C. Náquira, J. Godbillon, L. Miranda, 1998, British journal of clinical pharmacology.

The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects—male and female, elderly and young

J. McLeod, S. Osborne, J. Campestrini, 2001, Alimentary pharmacology & therapeutics.

Pharmacokinetics of carbamazepine in normal humans after single and repeated oral doses

A. Gérardin, W. Theobald, F. Abadie, 1976, Journal of Pharmacokinetics and Biopharmaceutics.

Pharmacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients.

J. Kovarik, D. Grant, G. Levy, 2001, Transplantation.

Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil.

H. Tedesco-Silva, C. Felipe, R. Schmouder, 2005, Transplantation proceedings.

Bioequivalence of vildagliptin/metformin fixed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjects.

S. Leon, Y.-L. He, V. Jarugula, 2008, International journal of clinical pharmacology and therapeutics.

Fully automated analytical system using liquid-solid extraction and liquid chromatography for the determination of CGP 6140 in plasma.

M. Rouan, J. Dubois, J. Lecaillon, 1988, Journal of Chromatography A.

Fast liquid chromatography for the determination of drugs in plasma and combination with liquid-solid extraction in a fully automated system.

M. Rouan, J. Godbillon, J. Lecaillon, 1992, Journal of chromatography.

Automated microanalysis of carbamazepine and its epoxide and trans-diol metabolites in plasma by column liquid chromatography.

M. Rouan, J. Godbillon, J. Lecaillon, 1992, Journal of chromatography.

Similar pharmacokinetics of tegaserod (HTF 919) in patients with constipation- and diarrhea-predominant irritable bowel syndrome

J. Rawls, J. Campestrini, R. Sechaud, 2000 .

Tegaserod does not significantly affect the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects

N. On, S. Osborne, J. Campestrini, 2000 .